Literature DB >> 34697194

Low Preoperative Albumin-to-Globulin Ratio Is a Marker of Poor Prognosis in Patients With Esophageal Cancer.

Yosuke Atsumi1, Shinnosuke Kawahara1, Sho Kakuta1, Atsushi Onodera1, Kentaro Hara1, Keisuke Kazama1, Masakatsu Numata1, Toru Aoyama1, Ayako Tamagawa1, Hiroshi Tamagawa1, Takashi Oshima2, Norio Yukawa1, Yasushi Rino1.   

Abstract

AIM: Recent studies have reported that the albumin-to-globulin ratio (AGR) may be a useful inflammatory-nutritional biomarker to predict postoperative complications and poor prognosis in various types of patients with cancer. However, its prognostic value in patients with esophageal cancer is still unclear. We aimed to examine the utility of the AGR for predicting the short- and long-term outcomes in patients with esophageal cancer who underwent curative resection. PATIENTS AND METHODS: This was a retrospective cohort analysis reviewing the medical records of consecutive patients who underwent esophagectomy for clinical stage I to III esophageal cancer at Yokohama City University. A total of 105 patients were identified between 2005 and 2018. The overall survival (OS), recurrence-free survival (RFS), and postoperative complication rates were compared between patients with high AGR (>1.48) and those with low AGR (≤1.48) group.
RESULTS: A total of 57 and 48 patients were classified into the high and low AGR groups, respectively. There was no significant difference between the two groups in the rate of overall postoperative complications of more than Clavien-Dindo grade 3 (50.9% vs. 54.2%, p=0.85). The long-term findings showed that 5-year OS and RFS rates were significantly better for the group with a high AGR (67.2% vs. 33.8%, p<0.001 and 51.6% vs. 28.5%, p=0.003, respectively).
CONCLUSION: This study suggests that a low preoperative AGR is a risk factor for poor RFS and OS in patients who are planning to undergo curative surgery for esophageal cancer. AGR may be a useful biomarker for establishing treatment strategies to improve patients' survival.
Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Esophageal cancer; albumin to globulin ratio; operative duration; risk factor

Mesh:

Substances:

Year:  2021        PMID: 34697194      PMCID: PMC8627716          DOI: 10.21873/invivo.12658

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  26 in total

Review 1.  Acute-phase proteins and other systemic responses to inflammation.

Authors:  C Gabay; I Kushner
Journal:  N Engl J Med       Date:  1999-02-11       Impact factor: 91.245

2.  The value of the pretreatment albumin/globulin ratio in predicting the long-term survival in colorectal cancer.

Authors:  Basem Azab; Shiksha Kedia; Neeraj Shah; Steven Vonfrolio; William Lu; Ali Naboush; Farhan Mohammed; Scott W Bloom
Journal:  Int J Colorectal Dis       Date:  2013-07-16       Impact factor: 2.571

3.  A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907).

Authors:  Nobutoshi Ando; Hoichi Kato; Hiroyasu Igaki; Masayuki Shinoda; Soji Ozawa; Hideaki Shimizu; Tsutomu Nakamura; Hiroshi Yabusaki; Norio Aoyama; Akira Kurita; Kenichiro Ikeda; Tatsuo Kanda; Toshimasa Tsujinaka; Kenichi Nakamura; Haruhiko Fukuda
Journal:  Ann Surg Oncol       Date:  2011-08-31       Impact factor: 5.344

4.  Prognostic Significance of Inflammatory and Nutritional Parameters in Patients with Esophageal Cancer.

Authors:  Tatsuya Miyazaki; Makoto Sakai; Makoto Sohda; Naritaka Tanaka; Takehiko Yokobori; Yoko Motegi; Masanobu Nakajima; Minoru Fukuchi; Hiroyuki Kato; Hiroyuki Kuwano
Journal:  Anticancer Res       Date:  2016-12       Impact factor: 2.480

5.  Investigation of the freely available easy-to-use software 'EZR' for medical statistics.

Authors:  Y Kanda
Journal:  Bone Marrow Transplant       Date:  2012-12-03       Impact factor: 5.483

Review 6.  Inflammation and cancer.

Authors:  Lisa M Coussens; Zena Werb
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

7.  Comparative Analysis of Immunoinflammatory and Nutritional Measures in Surgically Resected Esophageal Cancer: A Single-center Retrospective Study.

Authors:  Makoto Sakai; Makoto Sohda; Hideyuki Saito; Yasunari Ubukata; Nobuhiro Nakazawa; Kengo Kuriyama; Keigo Hara; Akihiko Sano; Kyoichi Ogata; Takehiko Yokobori; Ken Shirabe; Hiroshi Saeki
Journal:  In Vivo       Date:  2020 Mar-Apr       Impact factor: 2.155

Review 8.  Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability.

Authors:  Francesco Colotta; Paola Allavena; Antonio Sica; Cecilia Garlanda; Alberto Mantovani
Journal:  Carcinogenesis       Date:  2009-05-25       Impact factor: 4.944

9.  Low preoperative albumin-globulin score predicts favorable survival in esophageal squamous cell carcinoma.

Authors:  Fei Zhang; Peng Sun; Zhi-Qiang Wang; De Shen Wang; Yun Wang; Dong-Sheng Zhang; Feng-Hua Wang; Jian-Hua Fu; Rui-Hua Xu; Yu-Hong Li
Journal:  Oncotarget       Date:  2016-05-24

10.  Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2.

Authors:  Yuko Kitagawa; Takashi Uno; Tsuneo Oyama; Ken Kato; Hiroyuki Kato; Hirofumi Kawakubo; Osamu Kawamura; Motoyasu Kusano; Hiroyuki Kuwano; Hiroya Takeuchi; Yasushi Toh; Yuichiro Doki; Yoshio Naomoto; Kenji Nemoto; Eisuke Booka; Hisahiro Matsubara; Tatsuya Miyazaki; Manabu Muto; Akio Yanagisawa; Masahiro Yoshida
Journal:  Esophagus       Date:  2018-08-31       Impact factor: 3.671

View more
  5 in total

1.  The Platelet-to-Lymphocyte Ratio Is an Independent Prognostic Factor for Patients With Esophageal Cancer Who Receive Curative Treatment.

Authors:  Toru Aoyama; Miwa Ju; Keisuke Komori; Hiroshi Tamagawa; Ayako Tamagawa; Atsushi Onodera; Junya Morita; Itaru Hashimoto; Tetsushi Ishiguro; Kazuya Endo; Haruhiko Cho; Shizuνe Onuma; Momoko Fukuda; Takashi Oshima; Norio Yukawa; Yasushi Rino
Journal:  In Vivo       Date:  2022 Jul-Aug       Impact factor: 2.406

2.  Clinical Impact of Preoperative Albumin-Bilirubin Status in Esophageal Cancer Patients Who Receive Curative Treatment.

Authors:  Toru Aoyama; Mihwa Ju; Daisuke Machida; Keisuke Komori; Hiroshi Tamagawa; Ayako Tamagawa; Yukio Maezawa; Kazuki Kano; Kentaro Hara; Kenki Segami; Itaru Hashimoto; Shinsuke Nagasawa; Masato Nakazono; Takashi Oshima; Norio Yukawa; Yasushi Rino
Journal:  In Vivo       Date:  2022 May-Jun       Impact factor: 2.406

3.  Albumin and Neutrophil-to-Lymphocyte Ratio Score in Neoadjuvant Concurrent Chemoradiotherapy for Esophageal Cancer: Comparison With Prognostic Nutritional Index.

Authors:  William Harrison Hsueh; Shun-Wen Hsueh; Kun-Yun Yeh; Yu-Shin Hung; Ming-Mo Ho; Shinn-Yn Lin; Chen-Kan Tseng; Chia-Yen Hung; Wen-Chi Chou
Journal:  In Vivo       Date:  2022 Sep-Oct       Impact factor: 2.406

4.  Associations between albumin, globulin, albumin to globulin ratio and muscle mass in adults: results from the national health and nutrition examination survey 2011-2014.

Authors:  Zhi Chen; Chenyang Song; Zhipeng Yao; Jun Sun; Wenge Liu
Journal:  BMC Geriatr       Date:  2022-05-02       Impact factor: 4.070

5.  Clinical impact of pretreatment albumin-globulin ratio in patients with colorectal cancer: A meta-analysis.

Authors:  Jian-Ying Ma; Gang Liu; Liang-Zhi Pan; Min Hu; Zhong-Zhong Zhu
Journal:  Medicine (Baltimore)       Date:  2022-05-20       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.